GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Valuation Rank

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Valuation Rank


View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Zynerba Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » Valuation Rank
Comparable Companies
ALIM INIS AQST SCTL ELTP YCBD NLTX CLVR UNRV ACUR XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Website
http://www.zynerba.com
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
Kenneth T Jones officer: See Remarks C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger officer: VP, Commercial & Business Dev. C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree officer: President ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher officer: Chief Financial Officer C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido director, officer: Chairman & Chief Exec. Officer 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch director 68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper director NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson director C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici director 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker officer: Chief Legal Officer C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon officer: Sec, General Counsel & VP HR 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison director